“…[12][13][14][15] Cell saver system is commonly used for some procedures (cardiovascular, orthopedic surgery), 16,17 but it is a controversial technique in oncology because of the uncertain risk associated with the reinfusion of malignant cells during resections. 18 The evaluation of the above mentioned factors suggests that a targeted strategy, which would use PADB or ANH only in those patients who are at high risk of requiring a perioperative transfusion, may reduce the inconveniences and the cost associated with the use of these alternative techniques. In a recently-completed clinical trial, 19 we showed that red blood cell transfusion rates decrease from 25% to 13% by the use of ANH, but the decrease was substantially more pronounced in patients losing at least 800 mL of blood during the operation (from 43% to 18%).…”